iPSCs, a Universal Starting Material for Therapies
iPSCs are a viable option for use as a starting material for allogeneic cell therapies offering advantages and potential as a universal source.
Quality Considerations for a Growing Gene Therapy Field
Shorter timelines for clinical trials means being ready earlier for the quality requirements of late-stage trials and regulatory reviews.
Commercial Readiness Using 'Manufacturing by Design'
Allogeneic T-cell therapies are moving toward late-stage clinical trials and commercial registration with the promise of having these breakthrough therapies.